Hejna et al., (2001) recommended the topical use of GM-CSF for the treatment of CT-induced OM in patients with head and neck cancer since this topical treatment was effective on reducing the time of resolution of OM (P=0.0008) when compared to control. This evidence concerns the gene CSF2 and ocular melanoma.